Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1964 1
1965 11
1966 8
1967 6
1968 7
1969 11
1970 13
1971 13
1972 10
1973 10
1974 25
1975 26
1976 33
1977 28
1978 23
1979 14
1980 16
1981 39
1982 22
1983 37
1984 30
1985 35
1986 32
1987 30
1988 38
1989 29
1990 45
1991 40
1992 49
1993 38
1994 52
1995 51
1996 44
1997 50
1998 47
1999 37
2000 31
2001 29
2002 26
2003 54
2004 31
2005 33
2006 28
2007 32
2008 31
2009 25
2010 34
2011 38
2012 32
2013 36
2014 34
2015 30
2016 28
2017 40
2018 34
2019 25
2020 29
2021 24
2022 18
2023 24
2024 17

Text availability

Article attribute

Article type

Publication date

Search Results

1,674 results

Results by year

Filters applied: . Clear all
Page 1
Torsemide vs Furosemide Among Patients With New-Onset vs Worsening Chronic Heart Failure: A Substudy of the TRANSFORM-HF Randomized Clinical Trial.
Krim SR, Anand S, Greene SJ, Chen A, Wojdyla D, Vilaro J, Haught H, Herre JM, Eisenstein EL, Anstrom KJ, Pitt B, Velazquez EJ, Mentz RJ. Krim SR, et al. JAMA Cardiol. 2024 Feb 1;9(2):182-188. doi: 10.1001/jamacardio.2023.4776. JAMA Cardiol. 2024. PMID: 37955908 Clinical Trial.
There was no significant difference in mortality with torsemide vs furosemide in either de novo (No. of events [rate per 100 patient-years]: torsemide, 27 [7.4%] vs furosemide, 38 [10.9%]; aHR, 0.70; 95% CI, 0.40-1.14; P = .15) or WHF (torsemide 212 [26.8%] vs fu …
There was no significant difference in mortality with torsemide vs furosemide in either de novo (No. of events [rate per 100 patient- …
Clinical trial of a new diuretic, furosemide: comparison with hydrochlorothiazide and mercaptomerin.
Godwin TF, Gunton RW. Godwin TF, et al. Can Med Assoc J. 1965 Dec 18;93(25):1296-300. Can Med Assoc J. 1965. PMID: 5320846 Free PMC article. Clinical Trial.
A clinical trial was carried out with the object of comparing the effects of furosemide, a new oral diuretic agent, with those of mercaptomerin and hydrochlorothiazide. ...Urine electrolytes, body weight, and blood chemistry were monitored.Furosemide was shown to be …
A clinical trial was carried out with the object of comparing the effects of furosemide, a new oral diuretic agent, with those of mer …
Diuresis Efficacy in Ambulatory Congested Heart Failure Patients: Intrapatient Comparison of 3 Diuretic Regimens (DEA-HF).
Abbo AR, Gruber A, Volis I, Aronson D, Girerd N, Lund Kristensen S, Zukermann R, Alberkant N, Sitnitsky E, Kruger A, Khasis P, Bravo E, Elad B, Helmer Levin L, Caspi O. Abbo AR, et al. JACC Heart Fail. 2024 Aug;12(8):1396-1405. doi: 10.1016/j.jchf.2024.04.014. Epub 2024 May 11. JACC Heart Fail. 2024. PMID: 38739124 Clinical Trial.
Each patient received 3 different diuretic regimens: intravenous (IV) furosemide 250 mg; IV furosemide 250 mg plus oral metolazone 5 mg; and IV furosemide 250 mg plus IV acetazolamide 500 mg. ...CONCLUSIONS: In ambulatory CHF patients, furosemide plus …
Each patient received 3 different diuretic regimens: intravenous (IV) furosemide 250 mg; IV furosemide 250 mg plus oral metola …
Combining loop and thiazide diuretics for acute heart failure across the estimated glomerular filtration rate spectrum: A post-hoc analysis of the CLOROTIC trial.
Trullàs JC, Morales-Rull JL, Casado J, Carrera-Izquierdo M, Sánchez-Marteles M, Conde-Martel A, Dávila-Ramos MF, Llácer P, Salamanca-Bautista P, Chivite D, Jordana-Comajuncosa R, Villalonga M, Páez-Rubio MI, Manzano L, Formiga F. Trullàs JC, et al. Eur J Heart Fail. 2023 Oct;25(10):1784-1793. doi: 10.1002/ejhf.2988. Epub 2023 Aug 16. Eur J Heart Fail. 2023. PMID: 37540036 Free article. Clinical Trial.
AIMS: In patients with acute heart failure (AHF), the addition of hydrochlorothiazide (HCTZ) to furosemide improved diuretic response in the CLOROTIC trial. This work aimed to evaluate if these effects differ across the estimated glomerular filtration rate (eGFR) spectrum. …
AIMS: In patients with acute heart failure (AHF), the addition of hydrochlorothiazide (HCTZ) to furosemide improved diuretic response …
Intralesional combined digoxin and furosemide in plantar warts: Does it work?
Fathy G, Abo-Elmagd WM, Afify AA. Fathy G, et al. J Cosmet Dermatol. 2021 Aug;20(8):2606-2611. doi: 10.1111/jocd.13913. Epub 2021 Jan 3. J Cosmet Dermatol. 2021. PMID: 33389796 Clinical Trial.
DNA viruses rely on K + influx for replication. Both digoxin and furosemide inhibit the K + influx by interacting with cell membrane ion co-transporters. ...CONCLUSIONS: Intralesional injection of combined digoxin and furosemide is safe and effective treatment optio …
DNA viruses rely on K + influx for replication. Both digoxin and furosemide inhibit the K + influx by interacting with cell membrane …
Impact of baseline kidney dysfunction on oral diuretic efficacy following hospitalization for heart failure - insights from TRANSFORM-HF.
Martens P, Greene SJ, Mentz RJ, Li S, Wojdyla D, Kapelios CJ, Mullens W, Hall ME, Ketema F, Kim DY, Eisenstein EL, Anstrom K, Fang JC, Pitt B, Velazquez EJ, Tang WHW. Martens P, et al. Eur J Heart Fail. 2024 May;26(5):1242-1250. doi: 10.1002/ejhf.3207. Epub 2024 Apr 1. Eur J Heart Fail. 2024. PMID: 38558520 Clinical Trial.
METHODS AND RESULTS: The TRANSFORM-HF trial randomized patients hospitalized for HF to a long-term strategy of torsemide versus furosemide, and enrolled patients across the spectrum of renal function (without dialysis). ...CONCLUSION: Among patients discharged after hospit …
METHODS AND RESULTS: The TRANSFORM-HF trial randomized patients hospitalized for HF to a long-term strategy of torsemide versus furosemid …
The furosemide stress test predicts the timing of continuous renal replacement therapy initiation in critically ill patients with acute kidney injury: a double-blind prospective intervention cohort study.
Zhang K, Zhang H, Zhao C, Hu Z, Shang J, Chen Y, Huo Y, Zhao C, Li B, Guo S; Hebei Key Laboratory of Critical Disease Mechanism and Intervention. Zhang K, et al. Eur J Med Res. 2023 Apr 5;28(1):149. doi: 10.1186/s40001-023-01092-9. Eur J Med Res. 2023. PMID: 37020287 Free PMC article. Clinical Trial.
BACKGROUND: Continuous renal replacement therapy (CRRT) remains a crucial treatment for critically ill patients with acute kidney injury (AKI), although the timing of its initiation is still a matter of contention. Furosemide stress testing (FST) may be a practical and ben …
BACKGROUND: Continuous renal replacement therapy (CRRT) remains a crucial treatment for critically ill patients with acute kidney injury (AK …
Trial of Furosemide to Prevent Acute Kidney Injury in Critically Ill Children: A Double-Blind, Randomized, Controlled Trial.
Abraham S, Rameshkumar R, Chidambaram M, Soundravally R, Subramani S, Bhowmick R, Sheriff A, Maulik K, Mahadevan S. Abraham S, et al. Indian J Pediatr. 2021 Nov;88(11):1099-1106. doi: 10.1007/s12098-021-03727-3. Epub 2021 Apr 2. Indian J Pediatr. 2021. PMID: 33796993 Free PMC article. Clinical Trial.
RESULTS: The trial was stopped for futility, and data were analyzed on an intention-to-treat basis (furosemide-group: n = 38; placebo-group: n = 37). No significant difference was noted in the progression of AKI to a higher stage between furosemide and placebo group …
RESULTS: The trial was stopped for futility, and data were analyzed on an intention-to-treat basis (furosemide-group: n = 38; placebo …
On-treatment analysis of torsemide versus furosemide for patients hospitalized for heart failure: A post-hoc analysis of TRANSFORM-HF.
Kittipibul V, Mentz RJ, Clare RM, Wojdyla DM, Anstrom KJ, Eisenstein EL, Ambrosy AP, Goyal P, Skopicki HA, Ketema F, Kim DY, Desvigne-Nickens P, Pitt B, Velazquez EJ, Greene SJ. Kittipibul V, et al. Eur J Heart Fail. 2024 Jul;26(7):1518-1523. doi: 10.1002/ejhf.3293. Epub 2024 May 15. Eur J Heart Fail. 2024. PMID: 38745502 Clinical Trial.
AIM: The TRANSFORM-HF trial demonstrated no significant outcome differences between torsemide and furosemide following hospitalization for heart failure (HF), but may have been impacted by non-adherence to the randomized diuretic. The current study sought to determine the …
AIM: The TRANSFORM-HF trial demonstrated no significant outcome differences between torsemide and furosemide following hospitalizatio …
1,674 results